Company Thesis
Northwest Biotherapeutics' (NWBO) flagship product, DCVax (Dendritic cell vaccine for the treatment of glioblastoma) has seen its clinical investigation running well beyond schedule. While preliminary results on the entire study population are out, they raise more questions than answers as to what is happening behind the scenes. Moreover, the lack of any liquidity certainly does not help investors who have waited years for the announcement of fully unblinded results. Without further ado, let's take a look at why a biotech company with a promising drug can still become a poor investment